Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05388955
Other study ID # Riskcalculator.Pediatric.ntx
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1966
Est. completion date January 1, 2022

Study information

Verified date May 2022
Source Radboud University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Registry study in which data of all pediatric kidney recipients in the Netherlands (registered in the Nederlandse Orgaan Transplantatie Registry) are studied to develop a risk calculator for graft loss.


Description:

The pre-transplantation parameters of all recipients are used to do a multivariable regression analysis. The B-coefficients of this analysis will be used to develop a risk calculator that predicts graft survival after transplantation per year of transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 1425
Est. completion date January 1, 2022
Est. primary completion date January 1, 2022
Accepts healthy volunteers No
Gender All
Age group 0 Years to 18 Years
Eligibility Inclusion Criteria: Pediatric kidney recipients - transplantation in the Netherlands - signed informed consent Exclusion Criteria: - combined transplantation (pancreas-kidney of liver-kidney transplantation) - No informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
None, transplantation recipients
None, observational

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Radboud University Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Graft survival Functioning graft of death with functioning graft. Survival graph: Percentage recipients with a functioning graft over time Up to 50 years after transplantation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04057742 - AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
Recruiting NCT03465397 - Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients Phase 4
Completed NCT03437577 - Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients Phase 1/Phase 2
Not yet recruiting NCT05282966 - Assessment of QSantâ„¢ for Underlying Allograft Rejection
Recruiting NCT04388930 - The Microbiota in Kidney Donation and Transplantation
Completed NCT03611621 - A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Recruiting NCT05397821 - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Completed NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection
Active, not recruiting NCT05806749 - Immunological Tolerance in Patients With Mismatched Kidney Transplants Phase 1
Recruiting NCT04936282 - Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Phase 4
Enrolling by invitation NCT05285878 - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Phase 2
Recruiting NCT04526431 - Tacrolimus Pharmacokinetic Subpopulations
Active, not recruiting NCT03511560 - Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation Phase 4
Recruiting NCT03438773 - Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients Phase 1
Completed NCT06394596 - Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
Completed NCT04413916 - MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
Completed NCT03466775 - Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes N/A
Active, not recruiting NCT04733131 - Long-term Outcomes After Conversion to Belatacept
Active, not recruiting NCT03380962 - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Phase 1/Phase 2
Active, not recruiting NCT04154267 - Protocol Biopsies in High-risk Renal Transplant Recipients N/A

External Links